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Abstract  (237 words) 
Background: Ischemic postconditioning (PostC) protects the liver against ischemia-reperfusion (IR) 
injury.  Milrinone, a phosphodiesterase 3 inhibitor, has been reported to exhibit preconditioning 
properties against hepatic IR injury; however, its PostC properties remain unknown.  This study 
investigated whether milrinone has PostC properties against hepatic IR injury, and the roles of 
phosphatidylinositol 3-kinase (PI3K) and nitric oxide synthase (NOS). 
 
Materials and methods: Male Wistar rats were separated into six groups: (1) group S: animals that 
underwent sham operation without ischemia, (2) group C: ischemia followed by reperfusion with no 
other intervention, (3) group M: milrinone administered immediately after reperfusion, (4) group 
MW: wortmannin, a PI3K inhibitor, injected prior to milrinone administration, (5) group MN: 
L-NAME, a NOS inhibitor, injected prior to milrinone administration, and (6) group MD, milrinone 
administered 30 min after reperfusion.  Except for group S, all groups underwent 1 h of warm 
ischemia of median and left lateral lobes, followed by 5 h of reperfusion.  Biochemical liver 
function analysis and histological examination were performed.  
 
Results: Serum aspartate aminotransferase, alanine aminotransferase, and lactic dehydrogenase 
levels, histological damage scores, and apoptotic rate in group M were significantly lower than 
those in group C.  The inhibition of PI3K or NOS prevented this protective effect.  Milrinone 
administered 30 min after reperfusion did not show obvious protective effects. 
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Conclusions: Milrinone-induced PostC protects against hepatic IR injury when it is administered 








Major liver surgery, including partial hepatectomy with temporary portal inflow occlusion 
or liver donor preservation and transplantation, is inevitably associated with ischemia-reperfusion 
(IR) injury.  This hepatic IR injury still remains a factor that contributes to the morbidity and 
mortality after operation [1].  Various mechanisms have been implicated in hepatic IR injury, 
including reactive oxygen species (ROS), leukocyte migration and activation, microcirculatory 
abnormalities, sinusoidal endothelial cell damage, activation of the coagulation cascade, Kupffer 
cell activation due to the release of inflammatory cytokines, and mitochondrial dysfunction [2,3].  
Ischemic preconditioning (PreC), defined as brief periods of ischemia and reperfusion before 
sustained ischemia, is a promising approach to minimize hepatic IR injury in animals and humans 
[2-4].  Furthermore, recent studies have proved that several brief cycles of ischemia and 
reperfusion at the onset of sustained reperfusion after ischemia, termed ischemic postconditioning 
(PostC), provided protective effects against hepatic IR injury [5-7].  PostC is more likely than 
PreC to be feasible for clinical application because the onset of reperfusion is more predictable. 
 Although the mechanisms responsible for ischemic PostC of the liver are not as well 
characterized as those responsible for PreC, recent studies have shown that the two processes have 
many similarities, including adenosine- [8], phosphoinositide 3-kinase (PI3K)/Akt- [6], and 
endothelial and inducible nitric oxide synthase (eNOS and iNOS)-mediated NO production [5], as 
well as inhibition of the opening of the mitochondrial permeability transition pore (mPTP) [7].  
Similarly, studies have demonstrated that some agents, such as adenosine A2A receptor agonist [8], 
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recombinant erythropoietin (rhEPO) [9], and the volatile anesthetic sevoflurane [10], can be used as 
pharmacological inducers of PostC as well as PreC. 
 Milrinone, a phosphodiesterase 3 inhibitor (PDE-I), leads to sequential elevation of 
intracellular cyclic adenosine monophosphate (cAMP) and cAMP-dependent protein kinase (PKA) 
activation and exerts positive inotropic and vasodilatory effects [11].  Milrinone has been 
clinically used for the treatment of acute heart failure or low-output syndrome to facilitate 
functional recovery from myocardial dysfunction and to preserve the perfusion of major organs 
[12,13].  It has been reported that milrinone has PreC properties against hepatic IR injury via 
cAMP/PKA activation [14,15].  Milrinone-induced heart PostC is associated with the activation of 
PKA/Akt-dependent anti-apoptotic signaling [16].  Furthermore, studies have shown that 
cardioprotection is associated with NO production following Akt-mediated eNOS activation [17,18].  
Given the above background, we designed a study to evaluate the pharmacological PostC properties 
of milrinone against hepatic warm IR injury, and moreover to clarify the effect of milrinone 
administration time during reperfusion, that is, administration early and late after reperfusion.  We 
also examined whether milrinone-induced PostC could be mediated by PI3K and NOS. 
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2. Materials and methods 
 
 All experimental procedures and protocols described in this study were approved by the 
Institutional Animal Care and Use Committee of Nagasaki University School of Medicine, Japan. 
 
2.1. Materials 
 Milrinone was purchased from Astellas Pharma Co. (Tokyo, Japan).  The other chemicals 
and drugs used were purchased from Sigma (St. Louis, MO, USA) unless otherwise indicated.  
Wortmannin was dissolved in dimethyl sulfoxide and diluted tenfold with saline.  Milrinone and 
N-nitro-L-arginine methylester (L-NAME) were diluted and dissolved with saline. 
 
2.2. Surgical procedure and experimental protocol 
 Male Wistar rats weighing 320 to 430 g were anesthetized with pentobarbital sodium (a 50 
mg/kg intraperitoneal bolus).  A catheter was inserted into the right jugular vein for administering 
fluids or drugs.  Thereafter, 12 mg/kg/h pentobarbital in Ringer’s solution was infused at a rate of 
10 ml/kg/h until the experimental procedures had been completed.  After tracheotomy, the trachea 
was intubated with a cannula connected to a small animal ventilator (model SAR-830 CWE, PA, 
USA), and the lungs were ventilated with pure oxygen.  The abdominal cavity was approached 
through a midline incision and the liver was exposed.  At this point, all rats were divided into six 
groups (n = 10 each).  In groups C, M, MW, MN, and MD, total in- and outflows of the median 
7 
and left lateral hepatic lobes were occluded by a micro-vascular clip; this yielded approximately 
70% hepatic ischemia.  The abdomen was covered with saline-humidified gauze during the 
ischemic period.  After 60 min of partial hepatic ischemia, the clip was removed to initiate hepatic 
reperfusion, and the abdominal cavity was closed with a 4-0 silk suture.  During surgery, body 
temperature was monitored using a rectal probe and was maintained with a heating pad and heating 
lamp at 37°C.  Sham-operated animals (group S) went through the same surgical procedure as 
other animals; however, hepatic vessel clips were not applied.  In groups M, MW, and MN, 50 
μg/kg milrinone was administered as an i.v. bolus immediately after reperfusion.  In groups MW 
and MN, PI3K inhibitor wortmannin (0.6 mg/kg) and non-selective NOS inhibitor L-NAME (25 
mg/kg), respectively, were injected 5 min before the administration of milrinone.  In group MD, 50 
μg/kg milrinone was administered as an i.v. bolus 30 min after reperfusion.  In groups S and C, 
saline was infused at the same volume as milrinone, wortmannin, or L-NAME.  All animals were 
sacrificed 5 hours after reperfusion or sham surgery, and liver tissues and blood samples were taken 
for analysis. 
 
2.3. Liver function tests 
 Blood samples were taken from the inferior vena cava at the end of the experimental 
protocol.  The samples were centrifuged immediately at 3000 rpm for 10 min and then serum 
samples were stored at -80°C until analysis.  Serum aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), and lactate dehydrogenase (LDH) levels were determined by UV 
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spectrophotometric enzymatic assay. 
 
2.4. Histological examination 
 Liver tissue for histological examination was sampled from the left liver lobe at the end of 
the experimental protocol.  The specimens were fixed in 10% buffered formaldehyde solution, 
embedded in paraffin, and stained using hematoxylin and eosin (HE).  Histological analysis, based 
on the scoring system proposed by Suzuki et al. [19], was applied to all samples in order to 
determine the degree of sinusoidal congestion, liver cell vacuolization, and necrosis.  Histological 
changes were scored from 0 to 4. 
 
2.5. TUNEL staining 
 The presence of apoptotic cells in liver tissue was quantified by terminal deoxynucleotidyl 
transferase-mediated biotin nick end-labeling (TUNEL) staining.  The results were scored by 
counting the number of TUNEL-positive cells as a percentage of the total number of hepatocytes in 
6 random high-power fields (magnification ×400) per sample.  
 
2.6. Statistical analysis 
 The results are expressed as mean ± standard deviation.  Differences between 
experimental groups were analyzed by Student’s t test and one-way analysis of variance followed 
by the Student-Newman-Keuls test.  P < 0.05 was considered significant.  Statistical analysis was 
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 Eighty-three rats were used, with 60 successful experiments being achieved.  Eight rats 
were excluded as a result of technical difficulties with the experimental preparation.  Circulatory 
collapse or shock-induced death developed in 15 other rats before completion of the experiment; 4 
in the group C, 1 in the group M, 3 in the group MW, 4 in the group MN, 3 in the group MD.  
These rats were excluded from further analysis. 
 
3.1. Serum AST, ALT, and LDH levels (Fig. 1) 
 Compared with those in group S, the serum AST, ATL, and LDH levels at 5 hours after 
reperfusion significantly increased in groups C, M, MW, MN, and MD (P < 0.01).  In group M, the 
serum AST, ATL, and LDH levels were significantly lower than in group C (P < 0.01).  PI3K 
inhibitor wortmannin and non-selective NOS inhibitor L-NAME abolished the beneficial effects of 
milrinone-induced PostC.  There were no significant differences in the serum AST, ATL, and LDH 
levels between groups C and MD.   
 
3.2. Histological analysis 
 Histological analysis showed no pathological findings in group S.  According to Suzuki’s 
histological classification with HE staining, group C showed moderate to severe hepatocyte 
vacuolization with disruption of the lobular architecture and sinusoidal congestion (Fig. 2A); the 
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Suzuki score was 8.3 ± 1.5 (Fig. 3).  In groups MW, MN, and MD, the injury score was severe, as 
in group C.  Compared with group C, group M showed minimal hepatocyte vacuolization and 
sinusoidal congestion (Fig. 2B); the Suzuki score was 3.0 ± 1.2 (P < 0.05) (Fig. 3). 
 
3.3. Evaluation of hepatic apoptosis by TUNEL staining 
 The occurrence of apoptosis was suppressed in group M compared with that in group C 
(Fig. 2 and 4).  Meanwhile, in groups MW and MN, this protective effect was not shown.  In 






We investigated the pharmacological PostC properties of milrinone against hepatic warm 
IR injury, and the effect of administration timing or the potential mechanism involved.  It was 
observed that milrinone administered as an i.v. bolus immediately after reperfusion could 
effectively attenuate liver injury in a model of rat hepatic warm IR.  The protective effect of 
milrinone could be associated with the activation of PI3K and NOS that was abrogated by PI3K 
inhibition and NOS inhibition, respectively.  When milrinone was administered 30 min after 
reperfusion, the degree of liver function injury as determined by serum examination and histological 
analysis was not attenuated, while the occurrence of apoptosis was prevented.   
 Despite the protective effects of ischemic PreC against hepatic IR injury, its utilization as a 
clinical strategy is limited, mainly because it must be initiated before the ischemic event.  In 
deceased donor liver transplantation, although the onset of ischemia could not be predicted, the 
onset of reperfusion is more predictable.  Both ischemic PreC and PostC of the liver effectively 
reduced the generation of ROS, the expression of inflammatory cytokines, and apoptosis [20].  
Thus, PostC is more likely than PreC to be feasible for clinical application.  Although the 
mechanisms responsible for ischemic PostC of the liver are not fully understood, some studies have 
shown that the two processes have many similarities [6-8].  Recent studies have demonstrated that 
some agents, such as adenosine A2A receptor agonist [8], rhEPO [9], and sevoflurane [10], can be 
used as pharmacological inducers of PostC as well as PreC.  Milrinone has been shown to have 
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PreC properties using an orthotopic liver transplantation model and warm IR injury model in rats 
[14,15].  The present study is, to our knowledge, the first to demonstrate that milrinone also has 
PostC properties against hepatic warm IR injury. 
The onset of ischemic PreC is triggered by the production of adenosine and by the 
subsequent stimulation of A2A receptor.  A2A receptors have been shown to be coupled to Gs 
proteins that, through adenylate-cyclase, lead to sequential elevation of intracellular cAMP and 
PKA/PI3K activation [4].  The PI3K/Akt pathway is an important type of survival signaling that 
induces various anti-apoptotic molecules in ischemic PreC of the liver [21].  Our results show that 
pretreatment with a PI3K inhibitor, wortmannin, prevents milrinone-induced PostC of the liver.  
Ischemia- and A2A receptor agonist- or ginsenoside Rb1-induced PostC markedly enhanced Akt 
phosphorylation of the liver tissues at reperfusion, and attenuated hepatic warm IR injury [6,8,22].  
Dal Ponte et al. [8] also reported that pretreatment with a PI3K inhibitor prevented A2A receptor 
agonist-induced PostC of the liver.  Previous studies showed that milrinone administration 
stimulated immediate accumulation of cAMP and elevation of PKA in the liver tissue, and 
pretreatment with a PKA inhibitor prevented milrinone-induced PreC [14, 15].  In heart, 
milrinone-induced PostC also increased myocardial PKA activity and Akt phosphorylation, and 
reduced myocardial infarct size and myocyte apoptosis [16].  Thus, it is possible that 
milrinone-induced hepatic PostC is associated with the activation of PKA and the 
PI3K/Akt-dependent pathway.   
NO appears to be an essential endogenously generated molecule that protects against liver 
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IR injury [23].  The protective mechanisms of NO have been reported in that NO could reduce 
neutrophil adhesion to endothelial cells, platelet aggregation, ROS release, and inflammatory 
cytokine production, as well as ameliorate hepatic microvascular blood flow [23,24].  Our results 
show that pretreatment with a non-selective NOS inhibitor, L-NAME, prevents milrinone-induced 
PostC of the liver, which is consistent with previous reports [5,6].  Wang et al. [5] showed that the 
protective effect of ischemic PostC against hepatic IR injury is closely related to the NO production 
following the increase in eNOS and iNOS expression and the suppression of tumor necrosis 
factor-α and macrophage inflammatory protein-2 overproduction.  Guo et al. [6] demonstrated that 
ischemic PostC upregulated the concentrations of NO and attenuated the overproduction of ROS 
and inflammation, and these protective effects could be abolished by L-NAME.  NO may exert 
cytoprotective effects by preventing mPTP opening after reperfusion through a guanylyl cyclase 
and cyclic guanosine monophosphate-dependent kinase signaling pathway in hepatocytes [25].  A 
recent study has shown that the cytoprotective mechanism of ischemic PostC of the liver occurred 
through inhibition of the opening of mPTP at reperfusion.  Our previous study showed that 
atractyloside, an mPTP opener, prevents milrinone-induced PostC in rat heart [26].  We assume 
that milrinone can upregulate NOS activity of the liver, leading to inhibition of the opening of 
mPTP at reperfusion. 
 The early phase of reperfusion might be important for subsequent reperfusion injury, and 
manipulation of this early reperfusion phase was critical to the protective effect of ischemic PostC.  
When the maneuvering of ischemic PostC was delayed for a while, the protective effect was lost 
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[27].  Since then, PostC maneuvers were initiated within 1 min of reperfusion in the majority of 
studies.  However, a recent study demonstrated that ischemic PostC, when applied within 30 min 
after the onset of reperfusion, reduced infarct size and DNA fragmentation, and the degree of 
cardioprotection was inversely proportional to the delay of PostC application [28].  Thus, we 
studied the effect of milrinone administration time during reperfusion, that is, administration 
immediately or 30 min after reperfusion.  In the present study, milrinone administered 
immediately after reperfusion but not 30 min after reperfusion exerted obvious PostC properties on 
the liver.  It is possible that milrinone would need to be administered in the early phase of 
reperfusion to exert PostC properties.   
Several limitations of this study should be noted.  First, we studied only a single dose of 
milrinone in rats to examine milrinone-induced hepatic PostC.  The dose of milrinone treatment 
(50 µg/kg) used in this study corresponds to that applied clinically for a loading dose.  It is 
unfortunate that we cannot present the threshold of milrinone for hepatic PostC.  Second, we did 
not measure systemic hemodynamics such as blood pressure and heart rate in this study.  It has 
been shown that milrinone treatment (50 µg/kg) before liver ischemia [15], or after myocardial 
ischemia [16] did not affect systemic hemodynamics.  In another study, wortmannin or L-NAME 
administered 5 min before reperfusion also did not affect systemic hemodynamics in myocardial 
infarction models [29].  Taking these facts into consideration, it is not plausible that the present 
results could be attributed to the systemic hemodynamic changes induced by milrinone.  Third, we 
did not compare the effects of milrinone-induced PostC between orthotopic liver transplantation 
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model and warm IR injury model in rats.  Further studies are thus needed to apply the results of 
this experimental study to a clinical setting. 
In conclusion, PDE-I milrinone-induced PostC alleviated warm IR injury in rat liver.  
This protective effect was found when milrinone was administered immediately after reperfusion, 
but not 30 min after reperfusion.  Pretreatment of PI3K inhibitor or NOS inhibitor canceled this 
beneficial effect of milrinone.  We conclude that PI3K and NOS could play an important role in 
the protective effect by milrinone against hepatic IR injury. 
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Serum AST (A), ALT (B), and LDH (C) levels 5 hours after reperfusion.  *Significantly (P < 0.01) 
different from group S.  #Significantly (P < 0.01) different from group C.  Data are mean ± 
standard deviation (n = 10 in each group).  S = sham group, C = control group, M = milrinone 
group, MW = milrinone + wortmannin group, MN = milrinone + L-NAME group, MD = milrinone 
delayed by 30 min group 
 
Fig. 2 
Comparisons of histopathology for rat liver between control and M-treated groups.  A and B 
(Original magnification×400): Hematoxylin and eosin stains apparently reveals an ischemic change, 
such as hepatocytic atrophy with occasional cytoplasmic vacuolation and sinusoidal congestion at 
centrilobular area (zone 3) in control group (A) but not in M-treated group (B).  C and D (Original 
magnification×400): TUNEL-positive cells are found in the centrilobular area showing an ischemic 
change in the control group (C) but not in M-treated group (D).  Asterisks indicate the central vein. 
 
Fig. 3  
Analysis of Suzuki’s score.  *Significantly (P < 0.05) different from group S.  #Significantly (P < 
0.05) different from group C.  Data are mean ± standard deviation (n = 10 in each group).  S = 
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sham group, C = control group, M = milrinone group, MW = milrinone + wortmannin group, MN = 
milrinone + L-NAME group, MD = milrinone delayed by 30 min group 
 
Fig. 4 
Analysis of apoptosis index.  *Significantly (P < 0.05) different from group S.  #Significantly (P 
< 0.05) different from group C.  Data are mean ± standard deviation (n = 10 in each group).  S = 
sham group, C = control group, M = milrinone group, MW = milrinone + wortmannin group, MN = 
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